Can a gout drug cool down artery inflammation in diabetics?

NCT ID NCT04181996

Completed Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether colchicine, a drug used for gout, can reduce inflammation in the arteries of people with diabetes who recently had a heart attack or stroke. Researchers used a special PET scan to measure inflammation in the blood vessels. 115 participants were randomly assigned to receive colchicine or a placebo for 6 months. The goal was to see if colchicine could lower inflammation and potentially prevent future cardiovascular events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If it works, this could point toward a new way to prevent heart attacks and strokes in people with diabetes by targeting inflammation.
What could go wrong: This is a small, early-phase study (115 people) focused on imaging markers, not clinical events. Colchicine may not reduce inflammation enough or could cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute myocardial infarction atherosclerosis cardiovascular disorder diabetes mellitus Inflammation inflammatory disease ischemic stroke myocardial infarction prediabetes syndrome ST-elevation myocardial infarction transient ischemic attack type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROSIS CARDIOVASCULAR DISEASES DIABETES INFLAMMATION

Contacts and locations

Locations

Mazankowski Alberta Heart Institute

Edmonton, Alberta, T6G 2B7, Canada
University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.